As expected, inhibition of the PI3K pathway in vitro with PI3Kδ-specific idelalisib was shown to result in impaired homing of CLL cells to stromal cells, due to their reduced response to CXCL12 and CXCL13 (109). The gene discussed is CXCL13; the disease is B-cell chronic lymphocytic leukemia.